A controlled, randomized, delayed-start study
of rasagiline in early Parkinson disease
by
Parkinson Study Group.
Arch Neurol. 2004 Apr;61(4):561-6

ABSTRACT

BACKGROUND: Treatment with rasagiline mesylate, an irreversible monoamine oxidase type B inhibitor, improves symptoms of early Parkinson disease (PD). Preclinical studies suggest that this compound may also modify the progression of PD. OBJECTIVE: To compare the effects of early and later initiation of rasagiline on progression of disability in patients with PD. DESIGN: Double-blind, parallel-group, randomized, delayed-start clinical trial. SETTINGS AND PATIENTS: Four hundred four subjects with early PD, not requiring dopaminergic therapy, enrolled at 32 sites in the United States and Canada. INTERVENTIONS: Subjects were randomized to receive rasagiline, 1 or 2 mg/d, for 1 year or placebo for 6 months followed by rasagiline, 2 mg/d, for 6 months. MAIN OUTCOME MEASURE: Change in total Unified Parkinson's Disease Rating Scale score from baseline to 12 months. RESULTS: Three hundred seventy-one subjects were included in the 1-year efficacy analysis. Subjects treated with rasagiline, 2 mg/d, for 1 year had a 2.29-unit smaller increase in mean adjusted total Unified Parkinson's Disease Rating Scale score compared with subjects treated with placebo for 6 months followed by rasagiline, 2 mg/d, for 6 months (P =.01). The mean adjusted difference between the placebo/rasagiline, 2 mg/d, group and those receiving rasagiline, 1 mg/d, for 1 year was -1.82 unit on the Unified Parkinson's Disease Rating Scale score (P =.05). CONCLUSION: Subjects treated with rasagiline, 2 and 1 mg/d, for 12 months showed less functional decline than subjects whose treatment was delayed for 6 months.

MAOIs
Rasagiline
Neuroprotection
Rasagiline: structure
MAO-b inhibitors/PD
Anti-apoptotic activity
Molecular mechanisms
Rasagiline pharmacology
Parkinson's disease: resources
Anti-Alzheimer/anti-Parkinson's drugs
Rasagiline versus selegiline metabolites
Rasagiline/ anti-apoptotic bcl-2 gene family
Dual AChE and MAO inhibitors and Alzheimer's
Rasagiline v selegiline: neuronal survival effects
Rasagiline (Agilect) in early Parkinson's disease

Refs
HOME
HedWeb
Selegiline.com
BLTC Research
Nootropics.com
The Good Drug Guide
Paradise-Engineering
Supercentenarians.com
The Hedonistic Imperative
MDMA: Utopian Pharmacology